WO2019144759A1 - 靶向cdk4/6激酶抑制剂的晶型 - Google Patents
靶向cdk4/6激酶抑制剂的晶型 Download PDFInfo
- Publication number
- WO2019144759A1 WO2019144759A1 PCT/CN2018/124418 CN2018124418W WO2019144759A1 WO 2019144759 A1 WO2019144759 A1 WO 2019144759A1 CN 2018124418 W CN2018124418 W CN 2018124418W WO 2019144759 A1 WO2019144759 A1 WO 2019144759A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- cancer
- formula
- solvent
- group
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present disclosure relates to a crystalline form targeting a CDK4/6 kinase inhibitor and a process for the preparation thereof, and to pharmaceutical compositions comprising the crystalline form, and the activity of these compounds in reducing or inhibiting CDK4/6 kinase in cells, Use in the treatment and/or prevention of cancer-associated diseases mediated by CDK4/6 kinase.
- the chemical name of the compound represented by the formula (I) is 5-((4-ethylpiperazin-1-yl)methyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl) -2-methyl-1H-benzo[d]imidazol-6-yl)pyridin-2-ylpyrimidin-2-amine (hereinafter referred to as "the compound of formula (I)", in the patent application PCT/CN2014/095615 As described therein, it targets a cyclin-dependent kinase 4/6 (CDK4/6) kinase inhibitor. Studies have shown that CDK4/6 plays an irreplaceable role in the CDK subtype involved in the cell cycle.
- the cell cycle mutations associated with cancer are mainly present in the G1 and G1/S phase transformations.
- the complex formed by CDK4/6 and CyclinD phosphorylates the tumor suppressor gene Rb to pRb, releasing the bound transcription factor E2F, resulting in The S phase initiates the transcription of the relevant genes, prompting the cells to pass through the checkpoint and transfer from the G1 phase to the S phase.
- Abnormalities in the cyclin D-CDK4/6-INK4-Rb pathway are present in approximately 80% of human tumors.
- the change of this pathway accelerates the G1 phase process, which accelerates the proliferation of tumor cells and gains a survival advantage. Therefore, intervention in this pathway has become a therapeutic strategy, and CDK4/6 has become a new anti-tumor target.
- CDK4/6 as an anti-tumor target lies in the following two aspects: (1) Most proliferating cells rely on CDK2 or CDK4/6 proliferation, but CDK4/6 inhibitors do not exhibit "pan-CDK inhibitors" Cytotoxicity, such as myelosuppression and intestinal reactions. (2) Preclinical experiments show that if the level of cyclin D is increased or P16INK4a is inactivated, the sensitivity of the cells to drugs can be increased. Since the tumor cells have the above phenomenon relative to normal cells, the drug targeting is increased to some extent. Sex.
- crystal form plays an important role in the drug development process. Different crystal forms of the same drug have significant differences in solubility, stability and bioavailability. In order to better control the quality of the drug, the formulation is satisfied. For the requirements of production, transportation, storage, etc., we have studied the crystal form of the compound of formula (I) in order to find crystal forms with good properties.
- the present disclosure relates to a targeted CDK4/6 kinase inhibitor 5-((4-ethylpiperazin-1-yl)methyl)-N-(5-fluoro-4-(4-fluoro) represented by formula (I) Form A of 1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyridin-2-ylpyrimidin-2-amine.
- the present disclosure also relates to a process for the preparation of Form A, a pharmaceutical composition comprising Form A, and the activity of these compounds to reduce or inhibit CDK4/6 kinase in a cell, to treat and/or prevent mediated by CDK4/6 kinase Application in cancer-related diseases.
- the present disclosure provides a crystalline form A of a compound of formula (I),
- the crystalline form A of the compound of formula (I), in addition to the above characteristic peaks, is still 8.7 ⁇ 0.2 °, 10.9 ⁇ 0.2 °, 15.7 ⁇ 0.2 °, 16.4 ⁇ 0.2 °, There are characteristic peaks at 30.4 ⁇ 0.2°.
- the crystalline form A of the compound of formula (I) is still at 16.7 ⁇ 0.2 °, 19.3 ⁇ 0.2 °, 22.2 ⁇ 0.2 °, 23.3 ⁇ 0.2 °, 24.0 on the basis of the above characteristic peaks. Characteristic peaks at ⁇ 0.2°, 25.9 ⁇ 0.2°, and 28.1 ⁇ 0.2°.
- the crystalline form A of the compound of formula (I), which uses Cu-K alpha radiation represents the X-ray powder diffraction pattern at 2.6 ⁇ 0.2 °, 8.7 ⁇ 0.2 °, 10.0 ⁇ at 2 ⁇ angles. Characteristic peaks were present at 0.2°, 10.9 ⁇ 0.2°, 13.2 ⁇ 0.2°, 15.7 ⁇ 0.2°, 16.4 ⁇ 0.2°, 17.4 ⁇ 0.2°, 20.1 ⁇ 0.2°, 20.6 ⁇ 0.2°, and 30.4 ⁇ 0.2°.
- the crystalline form A of the compound of formula (I), which uses Cu-K alpha radiation represents the X-ray powder diffraction pattern at 2.6 ⁇ 0.2 °, 8.7 ⁇ 0.2 °, 10.0 ⁇ at 2 ⁇ angles. 0.2°, 10.9 ⁇ 0.2°, 13.2 ⁇ 0.2°, 15.7 ⁇ 0.2°, 16.4 ⁇ 0.2°, 16.7 ⁇ 0.2°, 17.4 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.1 ⁇ 0.2°, 20.6 ⁇ 0.2°, 22.2 ⁇ Characteristic peaks were found at 0.2°, 23.3 ⁇ 0.2°, 24.0 ⁇ 0.2°, 25.9 ⁇ 0.2°, 28.1 ⁇ 0.2°, and 30.4 ⁇ 0.2°.
- the crystalline form A of the compound of formula (I) has an X-ray powder diffraction pattern obtained substantially as shown in Figure 1 using Cu-K alpha radiation.
- DSC differential scanning calorimetry
- the crystalline form A of the compound of formula (I) has a differential scanning calorimetry (DSC) pattern substantially as shown in FIG.
- the crystalline form A of the compound of formula (I) is characterized by an X-ray powder diffraction pattern substantially as shown in FIG.
- the crystalline form A of the compound of formula (I) is characterized in that the differential scanning calorimetry chart has a draw in the range of about 195 ° C to 215 ° C, preferably in the range of 205 ⁇ 3 ° C.
- the heat peak, more preferably, the differential scanning calorimetry chart is substantially as shown in FIG.
- the crystalline form A of the compound of formula (I) is characterized by no significant weight loss in the range of 0 °C to 250 °C in the TGA spectrum, preferably having a heat substantially as shown in FIG. Reanalyze the graph.
- the crystalline form A of the compound of formula (I) is characterized by having a 1 H-NMR spectrum substantially as shown in FIG.
- the crystalline form A of the compound of formula (I) is characterized in that its crystal structure is in a substantially pure form.
- the present disclosure also provides a process for the preparation of the crystalline form A of the compound of formula (I), which comprises the following operations:
- the precipitated solid was collected.
- the method of preparing Form A of the compound of Formula (I) comprises the steps of:
- the precipitated solid was collected.
- the method of preparing Form A of the compound of Formula (I) comprises the steps of:
- the precipitated solid was collected and dried.
- the process for the preparation of Form A of the compound of Formula (I) which comprises dissolving a compound of Formula (I) in an organic solvent, heating to 60 ° C to 100 ° C, and stirring until the compound is dissolved Soon, the mixture was cooled and stirred to a temperature of 0 ° C to 25 ° C to precipitate a solid, and the mixture was stirred at a constant temperature for 1 to 24 hours, filtered under suction, and dried to obtain a crystal form A.
- the method of preparing Form A of the compound of Formula (I) comprises the steps of:
- the compound of formula (I) is dissolved in an organic solvent and heated to 70 ° C to 100 ° C;
- the temperature is lowered to 50 ° C to 75 ° C, seed crystals are added, the temperature is kept constant, and a solid is precipitated;
- the seed crystal is Form A of the compound of Formula (I) or a solid that precipitates during the preparation of Form A of the compound of Formula (I).
- the amount of the seed crystal added is from 0.1% to 3% by mass of the compound of formula (I), such as from 0.1% to 0.2%, from 0.2% to 0.5%, from 0.5% to 1%, 1%-1.5%, 1.5%-2%, 2%-2.5% or 2.5%-3%.
- the method of preparing Form A of the compound of Formula (I) comprises dissolving the compound of Formula (I) in an organic solvent, heating to 70 ° C to 100 ° C, and cooling the compound to 50 ° C after dissolution of the compound.
- a certain amount of seed crystals can be optionally added, constant temperature, solids appear, slowly cooled to 0 ° C ⁇ 25 ° C, constant temperature, suction filtration, and dried to obtain crystal form A.
- the seed crystal is selected from the form A or a solid precipitated before drying in the preparation of the crystal form A, and the crystal form A can be prepared by the preparation method of the other crystal form A without seeding described in the present disclosure. .
- the mass ratio of the seed crystal to the compound of the formula (I) is from 0.1% to 3%, preferably from 0.1% to 0.2%, from 0.2% to 0.5%, from 0.5% to 1%, from 1% to 1.5%, from 1.5% to 2%, 2 %-2.5%, 2.5%-3%.
- the method of preparing Form A of the compound of Formula (I) comprises the steps of:
- the compound of the formula (I) is dissolved in an organic solvent, heated to 70 ° C to 100 ° C, and after the compound is dissolved, the temperature is lowered to 50 ° C to 65 ° C, the seed crystal is added, the temperature is constant, and a solid appears, and the temperature is slowly lowered to 0 ° C to 25 ° C.
- the seed crystal is selected from the form A or the solid before drying in the process of preparing the crystal form A
- the mass ratio of the seed crystal to the compound of the formula (I) is 0.1 % to 3%, preferably 0.1% to 0.2%, 0.2% to 0.5%, 0.5% to 1%, 1% to 1.5%, 1.5% to 2%, 2% to 2.5%, 2.5% to 3%.
- the seed crystal is prepared by dissolving the compound of formula (I) in an organic solvent, heating to 60 ° C to 100 ° C, and stirring until the compound is dissolved, at a constant temperature, decreasing the stirring rate, and cooling. To 50 ° C ⁇ 65 ° C, increase the stirring rate, slowly reduce the temperature to 0 ° C ⁇ 25 ° C, precipitate solids, constant temperature, stirring for 1 ⁇ 24h, suction filtration to obtain seed crystals.
- the heating temperature is 60 ° C to 100 ° C, preferably 70 ° C to 100 ° C, preferably 80 ° C to 100 ° C, preferably 90 ° C to 100 ° C.
- the preferred heating temperature is the temperature at which the sample dissolves and becomes clear.
- the temperature is lowered to 0 ° C to 25 ° C, preferably 5 ° C to 10 ° C, preferably 5 ° C to 20 ° C, preferably 10 ° C to 15 ° C, Preferably, the temperature is from 15 ° C to 25 ° C, and the temperature can be optionally lowered at different temperatures during the cooling process.
- the cooling rate is preferably 3 to 15 ° C per hour, preferably 5 to 10 ° C / h, preferably 6 ° C / h, preferably 9 ° C / h; the cooling method includes but is not limited to natural cooling and cooling, ice bath cooling, oil bath cooling In the present disclosure, natural cooling and cooling, oil bath cooling, and cooling of the refrigeration equipment are preferred in the present disclosure.
- the stirring, the stirring mode includes, but not limited to, mechanical stirring, magnetic stirring, etc.; the stirring rate is preferably 500-100 r/min, preferably 300r/min, 150r/min (the speed can be adjusted according to the size of the stirring paddle. If the size of the stirring paddle is large, the rotation speed can be appropriately reduced), the stirring time is preferably 0.5h to 10h, preferably 0.5h to 1h, preferably 1h to 6h. It is preferably 1.5 h to 5 h.
- the compound of the formula (I) is dissolved in an organic solvent selected from one or more of the following solvents: Any combination between:
- an alcohol solvent selected from the group consisting of a fatty alcohol, an alicyclic alcohol, and an aromatic alcohol solvent selected from the group consisting of methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, and tert-butyl Alcohol, sec-butanol, n-pentanol, n-hexanol, ethylene glycol, propylene glycol or glycerol; said alicyclic alcohol solvent is selected from the group consisting of cyclopentanol, cyclopentanol, cyclohexanol, cyclohexane methanol or Cyclohexylethanol; the aromatic alcohol solvent is selected from the group consisting of benzyl alcohol, phenylethyl alcohol or phenylpropanol;
- a ketone solvent selected from the group consisting of aliphatic ketones and cycloketone solvents, wherein the aliphatic ketone solvent is selected from the group consisting of methyl ethyl ketone, methyl isopropyl ketone, acetone, methyl methyl ketone or methyl isobutyl ketone;
- the cycloketone solvent is selected from the group consisting of cyclopropanone, cyclohexanone, isophorone or N-methylpyrrolidone;
- a nitrile solvent selected from acetonitrile or propionitrile
- an ether solvent selected from the group consisting of a fatty ether and a cyclic ether solvent wherein the fatty ether solvent is selected from the group consisting of diethyl ether, dipropyl ether, diisopropyl ether, methyl tert-butyl ether, and ethyl butyl ether.
- the cyclic ether solvent is selected from the group consisting of ethylene oxide, 1,2-propylene oxide, tetrahydrofuran, 2-methylfuran, dioxolane or 1,4 - dioxane;
- An amide solvent selected from the group consisting of formamide, N,N-dimethylformamide, N,N-dimethylacetamide, N,N-dimethylpropionamide or N,N-diethylpropyl Amide
- a sulfoxide solvent selected from the group consisting of dimethyl sulfoxide, diethyl sulfoxide or benzyl sulfoxide;
- the "combination between any two or more kinds of solvents" as used in the organic solvent means a solvent in which the same type or different types of solvents are mixed in a predetermined ratio in the above organic solvent.
- Mixed solvents formed by the same type of solvent including but not limited to the following specific examples: methanol / ethanol, methanol / isopropanol, methanol / ethanol / isopropanol, methanol / tert-butanol, methanol / cyclopentanol, methanol / benzyl alcohol , ethanol / isopropanol, ethanol / tert-butanol, diethyl ether / tetrahydrofuran and the like.
- the mixed solvent formed by the different kinds of solvents includes, but is not limited to, the following mixed solvent systems: alcohols/ketones, alcohols/ethers, alcohols/amides, ketones/amides, and the like.
- the organic solvent is an alcohol solvent or a ketone solvent.
- the organic solvent is selected from the group consisting of acetone, isopropanol, butanol, n-pentanol.
- the drying method includes, but is not limited to, natural drying at room temperature, infrared lamp drying, oven drying, dryer drying, preferably in Drying under vacuum; preferably drying temperature is 30 ° C ⁇ 100 ° C, preferably 30 ° C ⁇ 80 ° C, preferably 35 ° C ⁇ 70 ° C, preferably 40 ° C ⁇ 65 ° C, preferably 35 ° C ⁇ 55 ° C; optional during the drying process
- the drying is carried out several times at different temperatures; the preferred drying time is 5h to 48h, 10h to 36h, and 15h to 24h.
- the present disclosure also provides pharmaceutical compositions comprising Form A of a compound of Formula (I) described herein, and optionally one or more pharmaceutically acceptable carriers and/or diluents.
- the pharmaceutical compositions of the present disclosure may be in any pharmaceutically acceptable dosage form, such as a solution, tablet, capsule or injection, which may be administered by the injection route or orally. medicine.
- Form A of the compound of Formula (I) described herein, or a pharmaceutical composition thereof, is preferably administered orally.
- a pharmaceutical composition comprising a crystalline form of (I) a compound (eg, Form A) and optionally one or more pharmaceutically acceptable carriers and/or diluents described herein may be pharmaceutically Acceptable in any dosage form. It is administered to a patient in need thereof by oral, parenteral, rectal or pulmonary administration.
- oral administration it can be prepared into a conventional solid preparation such as a tablet, a capsule, a pill, a granule or the like; or an oral liquid preparation such as an oral solution, an oral suspension, a syrup or the like.
- a suitable filler, a binder, a disintegrant, a lubricant, or the like may be added.
- parenteral administration it can be prepared as an injection, including an injection solution, a sterile powder for injection, and a concentrated solution for injection.
- injection When the injection is prepared, it can be produced by a conventional method in the prior art of pharmacy.
- no additive When the injection is formulated, no additive may be added, or a suitable additive may be added according to the nature of the drug.
- rectal administration When used for rectal administration, it can be made into a suppository or the like.
- pulmonary administration it can be prepared as an inhalant or a spray.
- the pharmaceutical compositions described herein may also comprise one or more additional anti-neoplastic agents and/or immunosuppressive agents.
- the additional anti-tumor agent and/or immunosuppressant is selected from one or more of the following: methotrexate, capecitabine, gemcitabine, deoxyfluorouridine, pemetrexed disodium , pazopanib, imatinib, erlotinib, lapatinib, gefitinib, vandetanib, herceptin, bevacizumab, rituximab, trastuzumab Anti-paclitaxel, vinorelbine, docetaxel, doxorubicin, hydroxycamptothecin, mitomycin, epirubicin, pirarubicin, bleomycin, letrozole, temoxi Fen, fulvestrant, triclinin, flutamide, leuprolide, anastrozole, ifosfamide, busulfan
- the present disclosure also provides a crystalline form (e.g., Form A) of a compound of Formula (I) of the present disclosure or a pharmaceutical composition of the present disclosure for use in the treatment and/or prevention of a subject by CDK4/ Use of a 6 kinase-mediated drug for cancer-related diseases.
- a crystalline form e.g., Form A
- a compound of Formula (I) of the present disclosure or a pharmaceutical composition of the present disclosure for use in the treatment and/or prevention of a subject by CDK4/ Use of a 6 kinase-mediated drug for cancer-related diseases.
- the present disclosure also provides a method of treating and/or preventing a cancer-associated disease mediated by CDK4/6 kinase in a mammal in need thereof, the method comprising administering a treatment to a mammal in need thereof And/or prophylactically effective amount of Form A of the compound of Formula (I) described herein or the pharmaceutical composition.
- the present disclosure also provides Form A of the compound of Formula (I) for use in the treatment and/or prevention of a drug associated with a CDK4/6 kinase mediated cancer associated disease.
- the CDK4/6 kinase-mediated cancer-related disease is selected from the group consisting of: brain tumor, lung cancer, squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, Cervical cancer, endometrial cancer, rectal cancer, liver cancer, kidney cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, prostate cancer, female genital tract cancer, carcinoma in situ, lymphoma, neurofibromatosis, thyroid cancer, bone Cancer, skin cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, prostate tumor, mast cell tumor, multiple myeloma, melanoma, glioma, sarcoma.
- each active ingredient in the pharmaceutical compositions of the present disclosure can be varied so that the resulting amount of active compound is effective to provide the desired therapeutic response to the particular patient, composition, and mode of administration.
- the dosage level will be selected based on the activity of the particular compound or its crystalline form, the route of administration, the severity of the condition being treated, and the condition and past medical history of the patient to be treated. However, it is the practice in the art that the dosage of the compound or its crystalline form begins at a level below that required to achieve the desired therapeutic effect, gradually increasing the dosage until the desired effect is achieved.
- a therapeutically and/or prophylactically effective amount of Form A of the compound of the present formula (I) may be applied in pure form.
- Form A of the compound of formula (I) can be administered as a pharmaceutical composition comprising Form A of a compound of Formula (I) and one or more pharmaceutically acceptable excipients.
- the phrase "therapeutically and/or prophylactically effective amount" of Form A of a compound of formula (I) as described herein refers to a sufficient amount of a compound to treat a disorder at a reasonable effect/risk ratio suitable for any medical treatment and/or prevention.
- the total daily usage of Form A and the pharmaceutical composition of the compounds of Formula (I) of the present disclosure is to be determined by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular patient will depend on a number of factors, including the disorder being treated and the severity of the disorder; the particular compound employed or its crystalline form of activity; Specific composition; age, weight, general health, sex and diet of the patient; time of administration, route of administration and excretion rate of the particular compound or crystalline form thereof used; duration of treatment; and specific compound or A drug whose crystalline form is used in combination or simultaneously; and similar factors well known in the medical field.
- the dosage of the compound or its crystalline form begins at a level below that required to achieve the desired therapeutic effect, gradually increasing the dosage until the desired effect is achieved.
- the dosage form A of the compound of formula (I) of the present disclosure for use in mammals, particularly humans may range from 0.001 to 1000 mg/kg body weight per day.
- Form A of the compound of formula (I) described in the present disclosure may be administered alone or in the form of a pharmaceutical composition.
- the pharmaceutical compositions described in the present disclosure may be formulated into various suitable dosage forms depending on the route of administration.
- the use of one or more physiologically acceptable carriers, including excipients and auxiliaries, facilitates processing of the active compound or its crystalline form into preparations which can be used pharmaceutically.
- the appropriate form of preparation will depend on the route of administration chosen and can be made according to common general knowledge in the art.
- the preparation method is simple and convenient, and is suitable for industrial production
- Figure 1 is an X-ray powder diffraction (XRPD) pattern of Form A of the compound of the formula (I), the ordinate indicates the diffraction intensity, and the abscissa indicates the diffraction angle (2 ⁇ ).
- XRPD X-ray powder diffraction
- Figure 3 is a 1H-NMR chart of Form A of the compound of formula (I).
- Preparation method 1 Take 5.0 g of the compound of the formula (I), add 75 mL of acetone, dissolve it under magnetic stirring, and immediately precipitate a white solid. After stirring for 5 h, suction and filter to obtain a white powder, which is dried under vacuum at 35 ° C for 16 h, and the obtained solid is subjected to XRPD test. , is crystal form A.
- Preparation method 2 Take 500 mg of the compound of the formula (I), add 15 mL of isopropanol, stir in an oil bath at 80 ° C, dissolve and become clear (within 4.0 h), naturally drop to room temperature (32 ° C), precipitate a white solid, at room temperature Stirring was continued for 12 h, the temperature was lowered to 15 ° C and stirred for 4.0 h, and suction filtered. The obtained solid was dried under vacuum at 45 ° C for 16 h, and analyzed by XRPD and 1 H-NMR.
- Preparation method 3 Take 5.0 g of the compound of the formula (I) in a 100 mL three-necked flask, add 75 mL of sec-butanol, control the temperature in an oil bath at 95 ° C, mechanically stir for 0.5 h, dissolve and become clear. Then, the temperature is lowered to 70 ° C in the oil bath, and about 25 mg of the seed crystal (that is, the crystal form A obtained in the first and second preparation methods) is added, and the white solid is gradually precipitated, and the temperature is further lowered to 60 ° C in the oil bath, the temperature is lowered for 0.5 h, and the temperature is lowered to 55 ° C.
- the seed crystal that is, the crystal form A obtained in the first and second preparation methods
- the purity of the crystal form A is more than 99.7%, the single maximum impurity is less than 0.08%, and almost no solvent remains.
- X-ray reflection parameters Cu, K ⁇ ; incident slit: 0.6 mm; divergence slit: 1 mm; scanning mode: continuous; scanning range: 3.0 to 45.0 degrees; sampling step size: 0.02 degrees; scanning time per step: 19.8 s; Detector angle: 2.0 degrees.
- Form A of the compound of formula (I) is shown in Figure 1 in an X-ray powder diffraction pattern having peaks at the following diffraction 2 ⁇ angles: 6.6 ⁇ 0.2 °, 8.7 ⁇ 0.2 °, 10.0 ⁇ 0.2 °, 10.9 ⁇ 0.2°, 13.2 ⁇ 0.2°, 15.7 ⁇ 0.2°, 16.4 ⁇ 0.2°, 16.7 ⁇ 0.2°, 17.4 ⁇ 0.2°, 19.3 ⁇ 0.2°, 20.1 ⁇ 0.2°, 20.6 ⁇ 0.2°, 22.2 ⁇ 0.2°, 23.3 ⁇ 0.2°, 24.0 ⁇ 0.2°, 25.9 ⁇ 0.2°, 28.1 ⁇ 0.2°, 30.4 ⁇ 0.2°.
- the measurement conditions were as follows: purging with nitrogen at 50 ml/min, collecting data at a heating rate of 10 ° C/min between 25 ° C and 220 ° C, and drawing with the endothermic peak facing downward.
- the crystal form A of the compound of the formula (I) showed an endothermic peak in the range of 195 ° C to 215 ° C, and the differential scanning calorimetry chart is shown in FIG. 2 .
- Test conditions Purging was performed with nitrogen at 60 ml/min, and data was collected at a heating rate of 10 ° C/min between room temperature and 350 °C.
- the crystal form A of the compound of the formula (I) has no significant weight loss in the range of 0 ° C to 250 ° C, and the TG curve thereof is shown in FIG. 2 .
- Test sample Form A of the compound of the formula (I), which was prepared according to the above production method one, two, three or four.
- test sample was placed under high humidity (25 ° C / RH 92.5% or 40 ° C / RH 75%) at 60 ° C for 10 days, sampling on the 5th and 10th day respectively; illumination (4500LX ⁇ 500LX)
- the cells were allowed to stand for 10 days, and samples were taken on the 10th day, and the relevant substances and XRPD were measured and compared with the samples of 0 days.
- the compound of formula (I) was prepared according to the preparation method of Example 1 of the specification in patent PCT/CN2014/095615.
- Form A of the compound of formula (I) is prepared according to the above preparation method one, two, three or four.
- Determination method According to the Chinese Pharmacopoeia 2015 edition of the four general rules 9103 drug wettability test guidelines.
- Test sample Form A of the compound of the formula (I), which was prepared according to the above production method one, two, three or four.
- Reagents Tween 80, ultrapure water.
- Equipment laser particle size analyzer, sample diffuser.
- test sample Take the appropriate amount of test sample, add 1% Tween 80 solution 0.1mL, to reduce the surface tension, use water as a dispersing agent to make a uniformly dispersed suspension, put it into the sample disperser, adjust the stirring speed to 2000rpm, ultrasonic The frequency was 7 KHz and the ultrasound was measured for 2 min.
- the particle size distribution of the crystal form A of the compound of the formula (I) is as follows: 10% of the sample is 2.501 ⁇ m or less, 50% is 10.432 ⁇ m or less, and 90% is 59.852 ⁇ m or less.
- Test article The compound of formula (I) (i.e., amorphous) was prepared according to the preparation method of Example 1 of the specification of Patent PCT/CN2014/095615.
- test sample was placed under the condition of 25 ° C / RH 92.5% or 60 ° C for 10 days, and samples were taken on the 5th and 10th day respectively; the test sample was exposed to light (4500LX ⁇ 500LX) or 40 °C / RH75 After 10 days under % conditions, samples were taken on the 10th day, and the relevant substances and XRPD were measured and compared with the samples of 0 days.
- the crystalline form A of the present disclosure exhibits good stability and low hygroscopicity characteristics, is convenient for the production of pharmaceuticals, preparation, transportation and storage of the preparation, and is more conducive to ensuring the stability and safety of the use of the medicine. Moreover, Form A has a better exposure and/or bioavailability in vivo than amorphous, and has good in vitro and in vivo effects.
- Test sample Form A of the compound of formula (I), prepared according to the above preparation method 1, 2, 3 or 4; the compound of formula (I) is not stereotyped, according to the preparation method of the embodiment 1 of the patent PCT/CN2014/095615 preparation.
- the crystal form A of the compound of the formula (I) and the amorphous material were separately tableted separately, the tablet weight was fixed, the tablet thickness (tableting force) was adjusted, and the tablet hardness was measured. Investigate the hardness as a function of the thickness of the tablet, and compare the compressibility.
- Test sample Form A of the compound of formula (I), prepared according to the above preparation method 1, 2, 3 or 4; the compound of formula (I) is not stereotyped, according to the preparation method of the embodiment 1 of the patent PCT/CN2014/095615 preparation.
- Form A and Amorphous were respectively added to the same kind and amount of auxiliary materials to prepare tablets, and disintegration and dissolution were examined under the following conditions.
- Dissolution method paddle method (Chinese Pharmacopoeia 2015 edition fourth part 0931 dissolution and release determination method second method); medium: 0.2% SDS aqueous solution; rotation speed: 50r / min.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (17)
- 如权利要求1所述的晶型A,其在使用Cu-Kα辐射,以2θ角度表示X-射线粉末衍射图在6.6±0.2°、8.7±0.2°、10.0±0.2°、10.9±0.2°、13.2±0.2°、15.7±0.2°、16.4±0.2°、17.4±0.2°、20.1±0.2°、20.6±0.2°、30.4±0.2°处有特征峰。
- 如权利要求1或2所述的晶型A,其在使用Cu-Kα辐射,以2θ角度表示X-射线粉末衍射图在6.6±0.2°、8.7±0.2°、10.0±0.2°、10.9±0.2°、13.2±0.2°、15.7±0.2°、16.4±0.2°、16.7±0.2°、17.4±0.2°、19.3±0.2°、20.1±0.2°、20.6±0.2°、22.2±0.2°、23.3±0.2°、24.0±0.2°、25.9±0.2°、28.1±0.2°、30.4±0.2°处有特征峰。
- 如权利要求1至3任一项所述的晶型A,其具有基本上如图1所示的使用Cu-Kα辐射获得的X-射线粉末衍射图。
- 如权利要求1至4任一项所述的晶型A,其在差示扫描量热分析(DSC)图谱中,在约195℃~215℃处存在一个吸热峰。
- 如权利要求1至5任一项所述的晶型A,其在差示扫描量热分析(DSC)图谱中,在205±3℃处存在一个吸热峰。
- 如权利要求1至6任一项所述的晶型A,其具有基本上如图2所示的差示扫描量热分析(DSC)图谱。
- 制备权利要求1-7任一项所述的式(I)化合物晶型A的方法,包括以下操作:将式(I)化合物溶于有机溶剂中,搅拌,收集析出的固体。
- 如权利要求8所述的制备方法,包括以下操作:将式(I)化合物溶于有机溶剂中,加热至60℃~100℃,搅拌使化合物溶解;降温至0℃~25℃,恒温搅拌1~24h;收集析出的固体,优选地,所述制备方法包括以下操作:将式(I)化合物溶于有机溶剂中,加热至60℃~100℃,搅拌使化合物溶解;降温至30℃~55℃,析出固体;降温至0℃~25℃,恒温搅拌1~24h;收集析出的固体,干燥,优选地,所述制备方法包括以下操作:将式(I)化合物溶于有机溶剂中,加热至60℃~100℃,并搅拌至化合物溶解为止,继续搅拌并降温至0℃~25℃,析出固体,恒温、搅拌1~24h,抽滤,干燥得到晶型A。
- 制备权利要求1-7任一项所述的式(I)化合物晶型A的方法,包括以下操作:将式(I)化合物溶于有机溶剂中,加热至70℃~100℃;化合物溶解后,降温至50℃~75℃,加入晶种,保持恒温,析出固体;缓慢降温至0℃~25℃,恒温,收集析出的固体,干燥得到晶型A,其中所述晶种为式(I)化合物晶型A或在制备式(I)化合物晶型A的过程中析出的固体,优选地,所加入的所述晶种的量为式(I)化合物的质量的0.1%~3%,例如0.1%~0.2%,0.2%-0.5%,0.5%-1%,1%-1.5%,1.5%-2%,2%-2.5%或2.5%-3%,优选地,所述的制备方法包括以下操作:将式(I)化合物溶于有机溶剂中,加热至70℃~100℃,化合物溶解后,降温至50℃~65℃时,加入晶种,恒温,出现固体,缓慢降温至0℃~25℃,恒温、抽滤,干燥得到晶型A,所述晶种选自晶型A或在制备晶型A的过程中干燥之前的固体,所述晶种与式(I)化合物的质量比为0.1%~3%,优选0.1%~0.2%,0.2%-0.5%,0.5%-1%,1%-1.5%,1.5%-2%,2%-2.5%,2.5%-3%。
- 如权利要求8-10任一项所述的制备晶型A的方法,其中所述的有机溶剂选自下列溶剂中的一种或者两种以上溶剂之间的任一组合:(1)醇类溶剂,选自脂肪醇、脂环醇及芳香醇类溶剂,所述脂肪醇类溶剂选自甲醇、乙醇、丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、仲丁醇、正戊醇、正己醇、乙二醇、丙二醇或丙三醇;所述的脂环醇类溶剂选自环戊醇、环戊甲醇、环己醇、环己甲醇或环己乙醇;所述芳香醇类溶剂选自苯甲醇、苯乙醇或苯丙醇;(2)酮类溶剂,选自脂肪酮类及环酮类溶剂,所述的脂肪酮类溶剂选自甲乙酮、 甲基异丙基酮、丙酮、甲基丁酮或甲基异丁酮;所述的环酮类溶剂选自环丙酮、环己酮、异佛尔酮或N-甲基吡咯烷酮;(3)腈类溶剂,选自乙腈或丙腈;(4)醚类溶剂,选自脂肪醚类及环醚类溶剂,所述脂肪醚类溶剂选自乙醚、二丙醚、二异丙醚、甲基叔丁基醚、乙基丁基醚、乙基叔丁基醚、二丁醚或二戊醚,环醚类溶剂选自环氧乙烷、1,2-环氧丙烷、四氢呋喃、2-甲基呋喃、二氧戊环或1,4-二氧六环;(5)酰胺类溶剂,选自甲酰胺、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、N,N-二甲基丙酰胺或N,N-二乙基丙酰胺;(6)亚砜类溶剂,选自二甲基亚砜、二乙基亚砜或苄苯亚砜,优选地,所述的有机溶剂为醇类溶剂或酮类溶剂,优选地,所述的有机溶剂选自:丙酮、异丙醇、丁醇、正戊醇。
- 药物组合物,其含有权利要求1-7任一项所述的式(I)化合物的晶型A,以及任选的一种或多种药用载体和/或稀释剂。
- 如权利要求12所述的药物组合物,其中还包含一种或多种额外的抗肿瘤剂和/或免疫抑制剂,所述额外的抗肿瘤剂和/或免疫抑制剂,选自下述中的一种或多种:甲氨蝶呤、卡培他滨、吉西他滨、去氧氟尿苷、培美曲塞二钠、帕唑帕尼、伊马替尼、埃罗替尼、拉帕替尼、吉非替尼、凡德他尼、赫赛汀、贝伐单抗、利妥昔单抗、曲妥珠单抗、紫杉醇、长春瑞滨、多西他赛、多柔比星、羟基喜树碱、丝裂霉素、表柔比星、吡柔比星、博来霉素、来曲唑、他莫西芬、氟维司群、曲谱瑞林、氟他胺、亮丙瑞林、阿那曲唑、异环磷酰胺、白消安、环磷酰胺、卡莫司汀、尼莫司汀、司莫司汀、氮芥、马法兰、瘤可宁、卡铂、顺铂、奥沙利铂、络铂、拓扑特肯、喜树碱、拓扑替康、依维莫司、西罗莫斯、特癌适、6-巯基嘌呤、6-硫鸟嘌呤、硫唑嘌呤、菌素D、柔红霉素、阿霉素、米托蒽醌、争光霉素、普卡霉素和氨鲁米特。
- 如权利要求1-7任一项所述的式(I)化合物的晶型A在制备用于治疗和/或预防受试者中由CDK4/6激酶介导的癌症相关疾病的药物中的用途。
- 一种在有需要的哺乳动物中治疗和/或预防由CDK4/6激酶介导的癌症相关疾病的方法,该方法包括给有需要的哺乳动物施用治疗和/或预防有效量的权利要求1-7任一项所述的式(I)化合物的晶型A或权利要求12-13任一项所述药物组合物。
- 如权利要求1-7任一项所述的式(I)化合物的晶型A,其用于治疗和/或预防 由CDK4/6激酶介导的癌症相关疾病的药物。
- 如权利要求14所示的用途,权利要求15所述的治疗和/或预防方法或权利要求15所述的式(I)化合物的晶型A,其中所述CDK4/6激酶介导的癌症相关疾病选自:脑瘤、肺癌、鳞状上皮细胞癌、膀胱癌、胃癌、卵巢癌、腹膜癌、胰腺癌、乳腺癌、头颈癌、子宫颈癌、子宫内膜癌、直肠癌、肝癌、肾癌、食管腺癌、食管鳞状细胞癌、前列腺癌、雌性生殖道癌、原位癌、淋巴瘤、神经纤维瘤、甲状腺癌、骨癌、皮肤癌、脑癌、结肠癌、睾丸癌、胃肠道间质瘤、前列腺肿瘤、肥大细胞肿瘤、多发性骨髓瘤、黑色素瘤、胶质瘤、肉瘤。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020562813A JP6972390B2 (ja) | 2018-01-29 | 2018-12-27 | Cdk4/6キナーゼ阻害剤を標的とする結晶形 |
EP18902212.2A EP3747880B1 (en) | 2018-01-29 | 2018-12-27 | Crystal form targeting cdk4/6 kinase inhibitor |
CN201880087850.6A CN111902405B (zh) | 2018-01-29 | 2018-12-27 | 靶向cdk4/6激酶抑制剂的晶型 |
KR1020207024721A KR102531772B1 (ko) | 2018-01-29 | 2018-12-27 | Cdk4/6 키나아제 억제제를 타겟팅하는 결정형 |
AU2018404690A AU2018404690B2 (en) | 2018-01-29 | 2018-12-27 | Crystal form targeting CDK4/6 kinase inhibitor |
EA202091556A EA202091556A1 (ru) | 2018-01-29 | 2018-12-27 | Кристаллическая форма ингибитора киназы cdk4/6 |
US16/965,503 US11299474B2 (en) | 2018-01-29 | 2018-12-27 | Crystal form targeting CDK4/6 kinase inhibitor |
CA3089243A CA3089243C (en) | 2018-01-29 | 2018-12-27 | Crystal form targeting cdk4/6 kinase inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810084351.3 | 2018-01-29 | ||
CN201810084351 | 2018-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019144759A1 true WO2019144759A1 (zh) | 2019-08-01 |
Family
ID=67394840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/124418 WO2019144759A1 (zh) | 2018-01-29 | 2018-12-27 | 靶向cdk4/6激酶抑制剂的晶型 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11299474B2 (zh) |
EP (1) | EP3747880B1 (zh) |
JP (1) | JP6972390B2 (zh) |
KR (1) | KR102531772B1 (zh) |
CN (1) | CN111902405B (zh) |
AU (1) | AU2018404690B2 (zh) |
CA (1) | CA3089243C (zh) |
EA (1) | EA202091556A1 (zh) |
WO (1) | WO2019144759A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020224609A1 (zh) * | 2019-05-08 | 2020-11-12 | 山东轩竹医药科技有限公司 | 激酶抑制剂的用途 |
WO2022143969A1 (zh) * | 2020-12-31 | 2022-07-07 | 轩竹生物科技股份有限公司 | 一种治疗癌症的药物组合物 |
WO2023109741A1 (zh) * | 2021-12-13 | 2023-06-22 | 轩竹生物科技股份有限公司 | 一种治疗癌症的药物组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010125004A1 (en) * | 2009-04-29 | 2010-11-04 | Nerviano Medical Sciences S.R.L. | Cdk inhibitor salts |
WO2015101293A1 (zh) * | 2013-12-31 | 2015-07-09 | 山东轩竹医药科技有限公司 | 激酶抑制剂及其用途 |
WO2016169422A1 (zh) * | 2015-04-22 | 2016-10-27 | 江苏恒瑞医药股份有限公司 | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110092775B (zh) * | 2018-01-29 | 2021-09-10 | 轩竹生物科技有限公司 | 靶向cdk4/6激酶抑制剂的晶型 |
-
2018
- 2018-12-27 EA EA202091556A patent/EA202091556A1/ru unknown
- 2018-12-27 AU AU2018404690A patent/AU2018404690B2/en active Active
- 2018-12-27 KR KR1020207024721A patent/KR102531772B1/ko active IP Right Grant
- 2018-12-27 CN CN201880087850.6A patent/CN111902405B/zh active Active
- 2018-12-27 US US16/965,503 patent/US11299474B2/en active Active
- 2018-12-27 JP JP2020562813A patent/JP6972390B2/ja active Active
- 2018-12-27 WO PCT/CN2018/124418 patent/WO2019144759A1/zh unknown
- 2018-12-27 EP EP18902212.2A patent/EP3747880B1/en active Active
- 2018-12-27 CA CA3089243A patent/CA3089243C/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010125004A1 (en) * | 2009-04-29 | 2010-11-04 | Nerviano Medical Sciences S.R.L. | Cdk inhibitor salts |
WO2015101293A1 (zh) * | 2013-12-31 | 2015-07-09 | 山东轩竹医药科技有限公司 | 激酶抑制剂及其用途 |
WO2016169422A1 (zh) * | 2015-04-22 | 2016-10-27 | 江苏恒瑞医药股份有限公司 | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 |
Non-Patent Citations (3)
Title |
---|
"Dissolution and Release Measurement methods, Method II", vol. IV, 2015, article "Chinese Pharmacopoeia", pages: 0931 |
"General Principles, 9103 Guiding Principles for Hygroscopicity Test on Drugs", vol. IV, 2015, article "Measured according to Chinese Pharmacopoeia", pages: 0451 |
See also references of EP3747880A4 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020224609A1 (zh) * | 2019-05-08 | 2020-11-12 | 山东轩竹医药科技有限公司 | 激酶抑制剂的用途 |
CN113811302A (zh) * | 2019-05-08 | 2021-12-17 | 山东轩竹医药科技有限公司 | 激酶抑制剂的用途 |
CN113811302B (zh) * | 2019-05-08 | 2023-12-29 | 山东轩竹医药科技有限公司 | 激酶抑制剂的用途 |
WO2022143969A1 (zh) * | 2020-12-31 | 2022-07-07 | 轩竹生物科技股份有限公司 | 一种治疗癌症的药物组合物 |
WO2023109741A1 (zh) * | 2021-12-13 | 2023-06-22 | 轩竹生物科技股份有限公司 | 一种治疗癌症的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
CA3089243A1 (en) | 2019-08-01 |
US11299474B2 (en) | 2022-04-12 |
AU2018404690A1 (en) | 2020-08-06 |
EA202091556A1 (ru) | 2021-02-19 |
CN111902405B (zh) | 2021-09-10 |
EP3747880A4 (en) | 2021-03-24 |
KR20200116132A (ko) | 2020-10-08 |
CN111902405A (zh) | 2020-11-06 |
KR102531772B1 (ko) | 2023-05-11 |
EP3747880A1 (en) | 2020-12-09 |
AU2018404690B2 (en) | 2021-05-06 |
JP2021512170A (ja) | 2021-05-13 |
EP3747880B1 (en) | 2023-05-03 |
JP6972390B2 (ja) | 2021-11-24 |
CA3089243C (en) | 2023-03-14 |
US20210047292A1 (en) | 2021-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110092775B (zh) | 靶向cdk4/6激酶抑制剂的晶型 | |
CN112010839B (zh) | 靶向丝/苏氨酸激酶抑制剂的晶型 | |
WO2019144759A1 (zh) | 靶向cdk4/6激酶抑制剂的晶型 | |
EP3279201B1 (en) | Cdk inhibitor, eutectic crystal of mek inhibitor, and preparation method therefor | |
TWI745289B (zh) | 一種週期素依賴性蛋白激酶抑制劑的結晶形式及其製備方法 | |
JP2021529175A (ja) | Cdk4/6活性阻害化合物の結晶形およびその使用 | |
EP3613746B1 (en) | Compound of eoc315 mod.i crystal form and preparation method therefor | |
WO2021047528A1 (zh) | 一个烟醇醚衍生物的马来酸盐及其晶型和应用 | |
JP6659850B2 (ja) | キノリン系化合物の塩、その結晶形、調製方法、組成物及び用途 | |
WO2016119646A1 (zh) | 一种舒尼替尼前药及药物组合物 | |
JP2015531355A (ja) | 腫瘍治療のための薬剤組成物及びその適用 | |
EA042455B1 (ru) | Кристаллическая форма ингибитора, нацеленного на киназу cdk4/6 | |
JP6656505B2 (ja) | オービットアジン−フマル酸塩、水和物、結晶形及びその調製方法 | |
CN112424172B (zh) | Hcv抑制剂的盐及其制备方法 | |
WO2021143819A1 (zh) | 多环类间变性淋巴瘤激酶抑制剂的晶型 | |
CN110248931B (zh) | 一种双加氧酶抑制剂的盐及其制备方法和用途 | |
WO2020045475A1 (ja) | ピラゾロ[3,4-d]ピリミジンの結晶 | |
CN106117199A (zh) | 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法 | |
TW202342041A (zh) | 一種藥物組合物及所含活性成分化合物的製備方法 | |
CN117562907A (zh) | 一种提升抗癌效果的可口服吉非替尼复合物及其制备方法与应用 | |
CN117447480A (zh) | E20在化疗致卵巢损伤保护中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18902212 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3089243 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020562813 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018404690 Country of ref document: AU Date of ref document: 20181227 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20207024721 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018902212 Country of ref document: EP Effective date: 20200831 |